Taligen gets $65m for complement programs.(Monday, Feb. 4)(Taligen Therapeutics Ink.)(Brief article)

Taligen Therapeutics Ink of Aurora, Colo., closed a tranched Series B financing round that eventually could bring the company as much as $65 million. Taiigen declined to specify how much money the company is getting up front or how the round is tranched but said the funding will last Taligen "several years;' and will allow the company to complete preclinical work and move into clinical trials with its drug candidates targeting complement proteins. Complement proteins, part of the innate …